An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort
Abstract Statins have been shown to induce a phosphoprotein signature that modifies MYC (myelocytomatosis viral oncogene) activation and to have anti‐inflammatory activity that may impact the risk of Non‐Hodgkin's lymphoma (NHL). We analyzed the relationship between statins and risk of NHL usin...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.1368 |
| _version_ | 1811154915167305728 |
|---|---|
| author | Pinkal Desai Robert Wallace Matthew L. Anderson Barbara V. Howard Roberta Ray Chunyuan Wu Monika Safford Lisa W. Martin Nicolas Schlecht Simin Liu Dominic Cirillo Allison Jay JoAnn E. Manson Michael S. Simon |
| author_facet | Pinkal Desai Robert Wallace Matthew L. Anderson Barbara V. Howard Roberta Ray Chunyuan Wu Monika Safford Lisa W. Martin Nicolas Schlecht Simin Liu Dominic Cirillo Allison Jay JoAnn E. Manson Michael S. Simon |
| author_sort | Pinkal Desai |
| collection | DOAJ |
| description | Abstract Statins have been shown to induce a phosphoprotein signature that modifies MYC (myelocytomatosis viral oncogene) activation and to have anti‐inflammatory activity that may impact the risk of Non‐Hodgkin's lymphoma (NHL). We analyzed the relationship between statins and risk of NHL using data from the Women's Health Initiative (WHI). The study population included 161,563 postmenopausal women ages 50–79 years from which 712 cases of NHL were diagnosed after 10.8 years of follow‐up. Information on statin use and other risk factors was collected by self‐ and interviewer‐administered questionnaires. Multivariable‐adjusted HR and 95% CI evaluating the relationship between statin use at baseline, as well as in a time‐dependent manner and risk of NHL, were computed from Cox proportional hazards analyses. A separate analysis was performed for individual NHL subtypes: diffuse large B‐Cell lymphoma (DLBCL) (n = 228), follicular lymphoma (n = 169), and small lymphocytic lymphoma (n = 74). All statistical tests were two‐sided. There was no significant association between use of statins at baseline and risk of NHL (HR 0.85, 95% C.I. 0.67–1.08). However, in the multivariable‐adjusted time‐dependent models, statin use was associated with a borderline lower risk of NHL (HR 0.81, 95% C.I. 0.66–1.00). Considering subtypes of NHL, statin use was associated with a lower risk of DLBCL (HR 0.62, 95% C.I. 0.42–0.91). This effect was driven by lipophilic statins (HR 0.62, 95% C.I. 0.40–0.96). In the WHI, statins were associated with a lower overall risk of DLBCL, particularly attributable to lipophilic statins. These results may have impact on primary or secondary prevention of NHL, particularly DLBCL. |
| first_indexed | 2024-04-10T04:25:15Z |
| format | Article |
| id | doaj.art-8de2154e18a94ec9a2b07f8b2265b118 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T04:25:15Z |
| publishDate | 2018-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-8de2154e18a94ec9a2b07f8b2265b1182023-03-10T15:42:22ZengWileyCancer Medicine2045-76342018-05-01752121213010.1002/cam4.1368An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohortPinkal Desai0Robert Wallace1Matthew L. Anderson2Barbara V. Howard3Roberta Ray4Chunyuan Wu5Monika Safford6Lisa W. Martin7Nicolas Schlecht8Simin Liu9Dominic Cirillo10Allison Jay11JoAnn E. Manson12Michael S. Simon13Weill Cornell Medical College New York New YorkDepartment of Epidemiology University of Iowa College of Public Health Iowa City IowaBaylor College of Medicine Houston TexasMedStar Health Research Institute and Georgetown/Howard Universities Center for Clinical and Translational Science Washington District of ColumbiaFred Hutchinson Cancer Research Center Seattle WashingtonFred Hutchinson Cancer Research Center Seattle WashingtonWeill Cornell Medical College New York New YorkGeorge Washington University Washington District of ColumbiaAlbert Einstein College of Medicine Bronx New YorkBrown University School of Public Health Providence Rhode IslandDepartment of Epidemiology University of Iowa College of Public Health Iowa City IowaSt John Providence Hospital Warren MichiganBrigham and Women's Hospital and Harvard Medical School Boston MassachusettsDepartment of Oncology Karmanos Cancer Institute Wayne State University Detroit MichiganAbstract Statins have been shown to induce a phosphoprotein signature that modifies MYC (myelocytomatosis viral oncogene) activation and to have anti‐inflammatory activity that may impact the risk of Non‐Hodgkin's lymphoma (NHL). We analyzed the relationship between statins and risk of NHL using data from the Women's Health Initiative (WHI). The study population included 161,563 postmenopausal women ages 50–79 years from which 712 cases of NHL were diagnosed after 10.8 years of follow‐up. Information on statin use and other risk factors was collected by self‐ and interviewer‐administered questionnaires. Multivariable‐adjusted HR and 95% CI evaluating the relationship between statin use at baseline, as well as in a time‐dependent manner and risk of NHL, were computed from Cox proportional hazards analyses. A separate analysis was performed for individual NHL subtypes: diffuse large B‐Cell lymphoma (DLBCL) (n = 228), follicular lymphoma (n = 169), and small lymphocytic lymphoma (n = 74). All statistical tests were two‐sided. There was no significant association between use of statins at baseline and risk of NHL (HR 0.85, 95% C.I. 0.67–1.08). However, in the multivariable‐adjusted time‐dependent models, statin use was associated with a borderline lower risk of NHL (HR 0.81, 95% C.I. 0.66–1.00). Considering subtypes of NHL, statin use was associated with a lower risk of DLBCL (HR 0.62, 95% C.I. 0.42–0.91). This effect was driven by lipophilic statins (HR 0.62, 95% C.I. 0.40–0.96). In the WHI, statins were associated with a lower overall risk of DLBCL, particularly attributable to lipophilic statins. These results may have impact on primary or secondary prevention of NHL, particularly DLBCL.https://doi.org/10.1002/cam4.1368NHLpreventionStatins |
| spellingShingle | Pinkal Desai Robert Wallace Matthew L. Anderson Barbara V. Howard Roberta Ray Chunyuan Wu Monika Safford Lisa W. Martin Nicolas Schlecht Simin Liu Dominic Cirillo Allison Jay JoAnn E. Manson Michael S. Simon An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort Cancer Medicine NHL prevention Statins |
| title | An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort |
| title_full | An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort |
| title_fullStr | An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort |
| title_full_unstemmed | An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort |
| title_short | An analysis of the effect of statins on the risk of Non‐Hodgkin's Lymphoma in the Women’s Health Initiative cohort |
| title_sort | analysis of the effect of statins on the risk of non hodgkin s lymphoma in the women s health initiative cohort |
| topic | NHL prevention Statins |
| url | https://doi.org/10.1002/cam4.1368 |
| work_keys_str_mv | AT pinkaldesai ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT robertwallace ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT matthewlanderson ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT barbaravhoward ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT robertaray ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT chunyuanwu ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT monikasafford ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT lisawmartin ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT nicolasschlecht ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT siminliu ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT dominiccirillo ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT allisonjay ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT joannemanson ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT michaelssimon ananalysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT pinkaldesai analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT robertwallace analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT matthewlanderson analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT barbaravhoward analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT robertaray analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT chunyuanwu analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT monikasafford analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT lisawmartin analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT nicolasschlecht analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT siminliu analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT dominiccirillo analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT allisonjay analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT joannemanson analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort AT michaelssimon analysisoftheeffectofstatinsontheriskofnonhodgkinslymphomainthewomenshealthinitiativecohort |